Embera NeuroTherapeutics

company

About

Embera NeuroTherapeutics is a development-stage pharmaceutical company developing treatments for smoking cessation and other addictions.

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
$11M
Industries
Biotechnology,Medical Device,Therapeutics
Founded date
Jan 1, 2005
Number Of Employee
11 - 50
Operating Status
Active

Embera NeuroTherapeutics is a development stage pharmaceutical company focused on developing treatments for smoking cessation and other addictions, for which there are a limited range of effective drug therapies or have no approved treatments. Embera is developing a novel addiction treatment (EMB-001) that targets specific and complementary brain functions that drive the craving and relapse associated with these disorders, an approach based on breakthrough discoveries of the scientific founder.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
$18.94M
Embera NeuroTherapeutics has raised a total of $18.94M in funding over 2 rounds. Their latest funding was raised on Dec 19, 2019 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 19, 2019 Grant 1 Rose Research Center (RRC) in North Carolina Detail
Jul 26, 2016 Grant $11M 1 National Institutes of Health Detail
Feb 26, 2015 Series A $2.34M 1 Detail
Aug 14, 2011 Series A $4.50M 2 Detail
Sep 15, 2008 Series Unknown $300K 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
5
Embera NeuroTherapeutics is funded by 5 investors. Rose Research Center (RRC) in North Carolina and National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
Rose Research Center (RRC) in North Carolina Yes Grant
National Institutes of Health Yes Grant
BVM Capital Series A
Louisiana Ventures Series A
Themelios Ventures Series A